This is a non-event for the stock — the $4M was already expected and merely completes the cash collection process. Monitor upcoming quarterly filings for cash runway and any new pipeline developments, as the company is now a post-divestiture entity with no new operational catalysts disclosed.
Price Chart
Executive Summary
Kyntra Bio received the final $4.0 million holdback from AstraZeneca related to the August 2025 sale of its China operations. No indemnity claims were made, completing collection of all ~$220 million in total consideration. This is a routine cash collection event with no new operational or strategic implications.
Key Facts
- Received $4.0 million from AstraZeneca on June 2, 2026 as final holdback under the Share Purchase Agreement.
- Total consideration for the sale of China operations was approximately $220 million ($85M enterprise value + ~$135M net cash).
- No indemnity claims were made against the $4.0 million holdback, so the full amount was released.
- All owed amounts under the Share Purchase Agreement have now been collected.
Financial Impact
Receipt of $4.0 million in cash, completing the ~$220 million total consideration from the sale of China operations.
Risk Factors
- No new revenue-generating operations or pipeline updates disclosed; cash burn rate and runway remain key unknowns.
- The company is now a smaller entity post-divestiture; risk of delisting or need for additional financing if cash is insufficient.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-264000 |
| Document: 0001193125-26-264000-index-headers.html | 0001193125-26-264000 |
| Document: 0001193125-26-264000-index.html | 0001193125-26-264000 |
| Document: 0001193125-26-264000.txt | 0001193125-26-264000 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 3 | $6.13 $5.57 | ▼ −9.22% | ▼ −8.24% | $4.50 (−26.59%) |
Oct 6, 2026 20d ago | 8-K | $6.13 $5.57 | ▲ +9.22% | ▲ +8.24% | $4.50 (+26.59%) |
Oct 1, 2026 25d ago | 8-K | $6.50 $5.96 | ▼ −8.31% | ▼ −9.61% | $4.50 (−30.77%) |
Jun 9, 2026 19w ago | 8-K | $6.69 $6.91 | ▲ +3.29% | ▼ −0.14% | $4.50 (−32.74%) |
May 11, 2026 24w ago | Press Release | $7.23 $6.83 | ▼ −5.47% | ▼ −5.54% | $4.50 (−37.72%) |
Mar 16, 2026 32w ago | Press Release | $7.37 $6.75 | ▲ +8.41% | ▲ +5.76% | $4.50 (+38.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers